0 223

Cited 2 times in

Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib

DC FieldValueLanguage
dc.contributor.author김건민-
dc.contributor.author최혜진-
dc.contributor.author한광협-
dc.contributor.author한정우-
dc.date.accessioned2016-02-04T11:55:34Z-
dc.date.available2016-02-04T11:55:34Z-
dc.date.issued2015-
dc.identifier.issn0815-9319-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/141504-
dc.description.abstractBACKGROUND AND AIM: Sorafenib is now considered as a standard treatment for advanced hepatocellular carcinoma (HCC). We evaluated the effect of hepatitis B virus (HBV) DNA titers on prognosis in HCC patients treated with sorafenib. METHODS: From 2008 to 2012, 78 HBV-related HCC patients who received sorafenib treatment at Severance Hospital were included in our analysis. The effect of pretreatment HBV-DNA levels on clinical outcomes for use in predicting prognosis after treatment with sorafenib was examined by univariate and multivariate analysis. RESULTS: Median overall survival and median progression-free survival were 5.2 months (95% confidence interval: 4.0-6.4) and 3.5 months (95% confidence interval: 2.3-4.7), respectively. Multivariate analysis revealed high levels of HBV-DNA (> 2000 IU/mL) to be an independent risk factor for worse overall survival (P=0.005; hazard ratio, 2.85) and disease progression among patients who did not receive concomitant prophylactic antiviral therapy during sorafenib treatment (P=0.008; hazard ratio, 87.4). Moreover, viral reactivation occurred more frequently in patients who did not receive concomitant prophylactic antiviral therapy than in those who did (4/38 vs 0/40; P=0.025). CONCLUSION: Higher HBV-DNA levels prior to sorafenib treatment were associated with poorer prognosis and increased viral reactivation thereafter. These results suggest the potential usefulness of prophylactic antiviral therapy when treating HBV-related HCC patients with sorafenib.-
dc.description.statementOfResponsibilityopen-
dc.format.extent1024~1031-
dc.relation.isPartOfJournal of Gastroenterology and Hepatology-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHAntineoplastic Agents/administration & dosage-
dc.subject.MESHAntineoplastic Agents/therapeutic use*-
dc.subject.MESHAntiviral Agents/administration & dosage*-
dc.subject.MESHBiomarkers/blood-
dc.subject.MESHCarcinoma, Hepatocellular/drug therapy*-
dc.subject.MESHCarcinoma, Hepatocellular/mortality-
dc.subject.MESHCarcinoma, Hepatocellular/virology-
dc.subject.MESHDNA, Viral/blood-
dc.subject.MESHDisease Progression-
dc.subject.MESHDrug Therapy, Combination-
dc.subject.MESHFemale-
dc.subject.MESHForecasting-
dc.subject.MESHHepatitis B virus*/genetics-
dc.subject.MESHHepatitis B virus*/physiology-
dc.subject.MESHHumans-
dc.subject.MESHLiver Neoplasms/drug therapy*-
dc.subject.MESHLiver Neoplasms/mortality-
dc.subject.MESHLiver Neoplasms/virology-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNiacinamide/administration & dosage-
dc.subject.MESHNiacinamide/analogs & derivatives*-
dc.subject.MESHNiacinamide/therapeutic use-
dc.subject.MESHPhenylurea Compounds/administration & dosage-
dc.subject.MESHPhenylurea Compounds/therapeutic use*-
dc.subject.MESHPrognosis-
dc.subject.MESHRisk Factors-
dc.subject.MESHSurvival Rate-
dc.subject.MESHViral Load*-
dc.subject.MESHVirus Activation-
dc.titleHepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorSeungtaek Lim-
dc.contributor.googleauthorJungwoo Han-
dc.contributor.googleauthorGun Min Kim-
dc.contributor.googleauthorKwang Hyub Han-
dc.contributor.googleauthorHye Jin Choi-
dc.identifier.doi10.1111/jgh.12898-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00287-
dc.contributor.localIdA04219-
dc.contributor.localIdA04268-
dc.contributor.localIdA04325-
dc.relation.journalcodeJ01417-
dc.identifier.pmid25611175-
dc.identifier.urlhttp://onlinelibrary.wiley.com/doi/10.1111/jgh.12898/abstract-
dc.subject.keywordhepatocellular carcinoma-
dc.subject.keywordsorafenib-
dc.subject.keywordviral load-
dc.contributor.alternativeNameKim, Gun Min-
dc.contributor.alternativeNameChoi, Hye Jin-
dc.contributor.alternativeNameHan, Kwang Hyup-
dc.contributor.alternativeNameHan, Jung Woo-
dc.contributor.affiliatedAuthorKim, Gun Min-
dc.contributor.affiliatedAuthorChoi, Hye Jin-
dc.contributor.affiliatedAuthorHan, Kwang Hyup-
dc.contributor.affiliatedAuthorHan, Jung Woo-
dc.rights.accessRightsnot free-
dc.citation.volume30-
dc.citation.number6-
dc.citation.startPage1024-
dc.citation.endPage1031-
dc.identifier.bibliographicCitationJournal of Gastroenterology and Hepatology, Vol.30(6) : 1024-1031, 2015-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아청소년과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.